This suggests that immune check-point inhibitors, targeting PD-1 or PD-L1, are effective for CNS prophylaxis in patients with PVRL or in patients with recurrent or refractory DLBCL-VRL when IL-35 levels are high in the vitreous humor at the initial diagnosis. This evidence concerns the gene CD274 and diffuse large B-cell lymphoma.